Age-related macular degeneration (AMD) is a leading cause of visual loss worldwide.[1] The introduction of anti-vascular endothelial growth factor (VEGF) treatment dramatically reduced the prevalence of legal blindness and visual impairment due to AMD.[2] However, anti-VEGF therapy does not cure AMD, and the primary goals of maintenance therapy are achieving control of disease activity and avoiding recurrences with minimal substantial sensory retinal impairment. This evidence concerns the gene VEGFA and age-related macular degeneration.